Phenobarbital use and neurological problems in FMR1 premutation carriers

Wilmar Saldarriaga, Pamela J Lein, Laura Yuriko González Teshima, Carolina Isaza, Lina Rosa, Andrew Polyak, Randi J Hagerman, Santhosh Girirajan, Marisol Silva, Flora Tassone

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by a CGG expansion in the FMR1 gene located at Xq27.3. Patients with the premutation in FMR1 present specific clinical problems associated with the number of CGG repeats (55-200 CGG repeats). Premutation carriers have elevated FMR1 mRNA expression levels, which have been associated with neurotoxicity potentially causing neurodevelopmental problems or neurological problems associated with aging. However, cognitive impairments or neurological problems may also be related to increased vulnerability of premutation carriers to neurotoxicants, including phenobarbital. Here we present a study of three sisters with the premutation who were exposed differentially to phenobarbital therapy throughout their lives, allowing us to compare the neurological effects of this drug in these patients.

Original languageEnglish (US)
Pages (from-to)141-147
Number of pages7
JournalNeuroToxicology
Volume53
DOIs
StatePublished - Mar 1 2016

Fingerprint

Phenobarbital
Fragile X Syndrome
Siblings
Genes
Aging of materials
Messenger RNA
Pharmaceutical Preparations
Therapeutics
Cognitive Dysfunction
Neurodevelopmental Disorders

Keywords

  • FMR1
  • Fragile X
  • Neurotoxicity
  • Pesticides
  • Phenobarbital
  • Premutation

ASJC Scopus subject areas

  • Neuroscience(all)
  • Toxicology

Cite this

Phenobarbital use and neurological problems in FMR1 premutation carriers. / Saldarriaga, Wilmar; Lein, Pamela J; González Teshima, Laura Yuriko; Isaza, Carolina; Rosa, Lina; Polyak, Andrew; Hagerman, Randi J; Girirajan, Santhosh; Silva, Marisol; Tassone, Flora.

In: NeuroToxicology, Vol. 53, 01.03.2016, p. 141-147.

Research output: Contribution to journalArticle

Saldarriaga, W, Lein, PJ, González Teshima, LY, Isaza, C, Rosa, L, Polyak, A, Hagerman, RJ, Girirajan, S, Silva, M & Tassone, F 2016, 'Phenobarbital use and neurological problems in FMR1 premutation carriers', NeuroToxicology, vol. 53, pp. 141-147. https://doi.org/10.1016/j.neuro.2016.01.008
Saldarriaga W, Lein PJ, González Teshima LY, Isaza C, Rosa L, Polyak A et al. Phenobarbital use and neurological problems in FMR1 premutation carriers. NeuroToxicology. 2016 Mar 1;53:141-147. https://doi.org/10.1016/j.neuro.2016.01.008
Saldarriaga, Wilmar ; Lein, Pamela J ; González Teshima, Laura Yuriko ; Isaza, Carolina ; Rosa, Lina ; Polyak, Andrew ; Hagerman, Randi J ; Girirajan, Santhosh ; Silva, Marisol ; Tassone, Flora. / Phenobarbital use and neurological problems in FMR1 premutation carriers. In: NeuroToxicology. 2016 ; Vol. 53. pp. 141-147.
@article{ee13a75af10d4fedb2fe1f845d4508e5,
title = "Phenobarbital use and neurological problems in FMR1 premutation carriers",
abstract = "Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by a CGG expansion in the FMR1 gene located at Xq27.3. Patients with the premutation in FMR1 present specific clinical problems associated with the number of CGG repeats (55-200 CGG repeats). Premutation carriers have elevated FMR1 mRNA expression levels, which have been associated with neurotoxicity potentially causing neurodevelopmental problems or neurological problems associated with aging. However, cognitive impairments or neurological problems may also be related to increased vulnerability of premutation carriers to neurotoxicants, including phenobarbital. Here we present a study of three sisters with the premutation who were exposed differentially to phenobarbital therapy throughout their lives, allowing us to compare the neurological effects of this drug in these patients.",
keywords = "FMR1, Fragile X, Neurotoxicity, Pesticides, Phenobarbital, Premutation",
author = "Wilmar Saldarriaga and Lein, {Pamela J} and {Gonz{\'a}lez Teshima}, {Laura Yuriko} and Carolina Isaza and Lina Rosa and Andrew Polyak and Hagerman, {Randi J} and Santhosh Girirajan and Marisol Silva and Flora Tassone",
year = "2016",
month = "3",
day = "1",
doi = "10.1016/j.neuro.2016.01.008",
language = "English (US)",
volume = "53",
pages = "141--147",
journal = "NeuroToxicology",
issn = "0161-813X",
publisher = "Elsevier",

}

TY - JOUR

T1 - Phenobarbital use and neurological problems in FMR1 premutation carriers

AU - Saldarriaga, Wilmar

AU - Lein, Pamela J

AU - González Teshima, Laura Yuriko

AU - Isaza, Carolina

AU - Rosa, Lina

AU - Polyak, Andrew

AU - Hagerman, Randi J

AU - Girirajan, Santhosh

AU - Silva, Marisol

AU - Tassone, Flora

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by a CGG expansion in the FMR1 gene located at Xq27.3. Patients with the premutation in FMR1 present specific clinical problems associated with the number of CGG repeats (55-200 CGG repeats). Premutation carriers have elevated FMR1 mRNA expression levels, which have been associated with neurotoxicity potentially causing neurodevelopmental problems or neurological problems associated with aging. However, cognitive impairments or neurological problems may also be related to increased vulnerability of premutation carriers to neurotoxicants, including phenobarbital. Here we present a study of three sisters with the premutation who were exposed differentially to phenobarbital therapy throughout their lives, allowing us to compare the neurological effects of this drug in these patients.

AB - Fragile X Syndrome (FXS) is a neurodevelopmental disorder caused by a CGG expansion in the FMR1 gene located at Xq27.3. Patients with the premutation in FMR1 present specific clinical problems associated with the number of CGG repeats (55-200 CGG repeats). Premutation carriers have elevated FMR1 mRNA expression levels, which have been associated with neurotoxicity potentially causing neurodevelopmental problems or neurological problems associated with aging. However, cognitive impairments or neurological problems may also be related to increased vulnerability of premutation carriers to neurotoxicants, including phenobarbital. Here we present a study of three sisters with the premutation who were exposed differentially to phenobarbital therapy throughout their lives, allowing us to compare the neurological effects of this drug in these patients.

KW - FMR1

KW - Fragile X

KW - Neurotoxicity

KW - Pesticides

KW - Phenobarbital

KW - Premutation

UR - http://www.scopus.com/inward/record.url?scp=84955588792&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84955588792&partnerID=8YFLogxK

U2 - 10.1016/j.neuro.2016.01.008

DO - 10.1016/j.neuro.2016.01.008

M3 - Article

C2 - 26802682

AN - SCOPUS:84955588792

VL - 53

SP - 141

EP - 147

JO - NeuroToxicology

JF - NeuroToxicology

SN - 0161-813X

ER -